| Mesalamine in the treatment and maintenance of remission of ulcerative colitis. | |
| | |
MedLine Citation:
|
PMID: 22390554 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Ulcerative colitis (UC) is a chronic disease of the GI tract that is characterized by mucosal inflammation in the colon. Mesalamine (mesalazine) is a 5-aminosalicylic acid compound that is the first-line treatment for patients with mild-to-moderate UC. There are multiple formulations of mesalamine available, primarily differentiated by their means of delivering active mesalamine to the colon. Mesalamine has been demonstrated in randomized controlled trials to induce both clinical response and remission, and maintain clinical remission, in these patients. It has few serious adverse effects and is generally well tolerated by patients. The main areas of uncertainty with use of mesalamine in patients with UC center on the optimal dose for induction of response, how to maintain patient adherence and the role of mesalamine in cancer chemoprophylaxis. Generic forms of mesalamine have yet to be approved by regulatory bodies in the USA. |
| | |
Authors:
|
Maggie Ham; Alan C Moss |
Related Documents
:
|
17170874 - Limits of the transoral approach in craniospinal malformations. 6483134 - Modified crossed leg raising test and sciatica. 20674124 - Effects of class iii malocclusion on young male adults' vocal tract development: a pilo... 21397424 - Presence of anti-borrelia burgdorferi antibodies and borrelia burgdorferi sensu lato dn... 3377464 - Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing... 9373264 - Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superi... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review |
Journal Detail:
|
Title: Expert review of clinical pharmacology Volume: 5 ISSN: 1751-2441 ISO Abbreviation: Expert Rev Clin Pharmacol Publication Date: 2012 Mar |
Date Detail:
|
Created Date: 2012-03-06 Completed Date: 2012-05-29 Revised Date: 2013-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 101278296 Medline TA: Expert Rev Clin Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 113-23 Citation Subset: IM |
Affiliation:
|
Center for Inflammatory Bowel Disease, BIDMC/Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Aged, 80 and over Anti-Inflammatory Agents, Non-Steroidal / adverse effects, pharmacology, therapeutic use* Child Child, Preschool Colitis, Ulcerative / complications, drug therapy* Humans Infant Mesalamine / adverse effects, pharmacology, therapeutic use* Middle Aged Patient Compliance Randomized Controlled Trials as Topic Remission Induction Severity of Illness Index Therapeutic Equivalency Treatment Outcome Young Adult |
| Grant Support | |
ID/Acronym/Agency:
|
K23 DK084338-01A2/DK/NIDDK NIH HHS; K23DK084338/DK/NIDDK NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents, Non-Steroidal; 89-57-6/Mesalamine |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Treatment of Localized Gingival Recessions Using Gingival Unit Grafts: A Randomized Controlled Clini...
Next Document: Octreotide long-acting repeatable for acromegaly.